Galectin Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -11.0% | -40.2% | -73.7% | +116.4% | +438.2% | -38.9% | +41.3% | -49.1% | +32.5% | -38.0% | +11.6% | |
| – | -11.0% | -40.2% | -75.8% | +131.3% | +445.8% | -38.9% | +41.9% | -50.9% | +34.8% | -37.7% | +12.7% | |
| – | -11.3% | -40.6% | -80.1% | +170.3% | +475.3% | -42.8% | +46.1% | -53.1% | +38.0% | -41.1% | +17.2% | |
| – | -11.3% | -40.6% | -80.1% | +170.3% | +475.3% | -42.8% | +46.1% | -53.1% | +38.0% | -41.1% | +17.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | – | – | – | -42.9% | -85.4% | – | – | – | – | |
| – | -46.7% | -87.5% | -100.0% | – | – | – | – | – | – | – | – | |
| – | -46.7% | -87.5% | -100.0% | – | – | – | – | – | – | – | – | |
| – | -20.1% | +177.9% | -21.5% | -29.0% | +36.2% | +88.3% | +625.2% | +36.4% | +65.4% | +36.3% | +20.9% | |
| – | -20.1% | +177.9% | -21.5% | -29.0% | +33.8% | +91.5% | +67.3% | +44.0% | +20.5% | +125.9% | -77.3% | |
| – | – | – | – | – | – | +12.8% | -81.8% | +400.0% | +15.0% | +45,847.8% | -99.9% | |
| – | -50.6% | +103.1% | -33.2% | -51.2% | +459.3% | -22.2% | +39.7% | +115.5% | +65.3% | -12.1% | -42.6% | |
| – | – | – | – | – | – | – | – | +37.1% | +80.1% | +18.6% | +57.1% | |
| – | -10.5% | -52.0% | -90.1% | +478.2% | +561.0% | -46.9% | -89.2% | -1,330.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.4% | +21.1% | +21.6% | +11.0% | +32.5% | +9.2% | +2.6% | +1.5% | +1.3% | +3.6% | +2.6% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.